Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
Baxter
Covington
Merck
Johnson and Johnson
Harvard Business School
UBS
Cantor Fitzgerald
Chubb

Generated: May 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,004,565

« Back to Dashboard

Summary for Patent: 6,004,565
Title: Compositions and methods of using compositions with accelerated lymphocyte homing immunosuppressive properties
Abstract:The methods and compositions of the invention and the compounds used in the invention involve a novel immunosuppression mechanism, accelerated lymphocyte homing immunosuppression (ALH-immunosuppression). For example, the compound FTY720 specifically directs lymphocytes to the peripheral lymph nodes, mesenteric lymph nodes, and Peyer's patches. By reversibly sequestering lymphocytes in these tissues, the compounds can inhibit an immune response in a mammal. Understanding these mechanisms provides a novel immunosuppression therapy that can synergistically interact with other immunosuppressive compounds. Screening methods for identifying similar ALH-immunosuppression compounds are also described. The invention allows better treatments and therapies wherever an immunosuppression regimen is desired.
Inventor(s): Chiba; Kenji (Fukuoka, JP), Adachi; Kunitomo (Fukuoka, JP)
Assignee: Yoshitomi Pharmaceutical Industries, Ltd. (Osaka, JP)
Application Number:08/933,738
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,004,565
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form;

Drugs Protected by US Patent 6,004,565

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,004,565

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan9-237273Sep 02, 1997

International Family Members for US Patent 6,004,565

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Japan H1180026 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Johnson and Johnson
Julphar
Deloitte
Daiichi Sankyo
Harvard Business School
Express Scripts
Colorcon
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.